Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 16,855 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Disease Clear all
Completed No phase listed Observational

Prevention of Retained-Blood Outcomes With Active Clearance Technology

NCT02145858
View directory record Official record
Conditions
Hemorrhage, Atrial Fibrillation, Postoperative
Interventions
Blood drainage post cardiac surgery using PleuraFlow System
Device
Lead sponsor
ClearFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Manchester, New Hampshire • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 15, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura

NCT00601848
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
chemotherapy, porfimer sodium, immunohistochemistry staining method, laboratory biomarker analysis, spectroscopy, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 15, 2026, 4:55 PM EDT
Withdrawn No phase listed Observational

Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change

NCT02061943
View directory record Official record
Conditions
Spasmodic Dysphonia, Laryngeal Dystonia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Influenza Virus Vaccines in Children and Adults

NCT00988143
View directory record Official record
Conditions
Influenza
Interventions
2009-2010 Trivalent Influenza Virus Vaccine, 2008-2009 Trivalent Influenza Virus Vaccine, Quadrivalent Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Durham, North Carolina • Cincinnati, Ohio • Jefferson Hills, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00622635
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

NCT03242915
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Carboplatin, Pemetrexed
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
7
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

NCT00091715
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
bosentan, placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Torrance, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

NCT05077709
View directory record Official record
Conditions
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
Interventions
IO102-IO103 in combination with pembrolizumab
Drug
Lead sponsor
IO Biotech
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Duarte, California • Sacramento, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults

NCT03444298
View directory record Official record
Conditions
Airway Inflammation, Asthma
Interventions
Gamma Tocopherol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 15, 2026, 4:55 PM EDT
Not listed Not applicable Interventional

Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

NCT05866198
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Actigraph CP Insight Watch
Diagnostic Test
Lead sponsor
University of South Florida
Other
Eligibility
40 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

NCT01366521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 15, 2026, 4:55 PM EDT
Terminated Phase 4 Interventional Results available

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

NCT01760304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide / Formoterol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

NCT01545947
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions
CC-223, erlotinib, CC-223, oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 15, 2026, 4:55 PM EDT
Completed No phase listed Observational

Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)

NCT01173458
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Kansas City, Kansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 4 Interventional

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 15, 2026, 4:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma

NCT05341726
View directory record Official record
Conditions
Asthma
Interventions
BREATHE Intervention, Control Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Beacon, New York • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance

NCT04895085
View directory record Official record
Conditions
COVID-19, Children With Medical Complexity (CMC)
Interventions
BinaxNOW Rapid Antigen System
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 15, 2026, 4:55 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)

NCT02687815
View directory record Official record
Conditions
Asthma
Interventions
vitamin D3 4000 IU, Placebo
Drug
Lead sponsor
Juan Celedon, MD
Other
Eligibility
6 Years to 16 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 15, 2026, 4:55 PM EDT
Active, not recruiting No phase listed Observational

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

NCT04056247
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma
Interventions
Plasma sample collection
Other
Lead sponsor
OncoHost Ltd.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 4:55 PM EDT
Enrolling by invitation Phase 3 Interventional

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

NCT05844449
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
1 Year and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
Orange, California • Palo Alto, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 4:55 PM EDT
Terminated Phase 1 Interventional Results available

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

NCT05374538
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
VIC-1911, sotorasib
Drug
Lead sponsor
Vitrac Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 15, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

NCT00525148
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 15, 2026, 4:55 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07536308
View directory record Official record
Conditions
COVID-19
Interventions
OCU500
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Decatur, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 4:55 PM EDT